Feline Obesity Targeted by New 'Ozempic'-Like Drug Trial for Cats
Experts estimate that approximately 60% of cats in America are overweight, which contributes to a rise in feline diabetes cases.
A novel weight reduction treatment for pets, which utilizes the same drug category as well-known human medications like Ozempic and Wegovy, is undergoing testing in cats.
Based in San Francisco, OKAVA Pharmaceuticals has initiated the first clinical trial globally of a GLP-1 therapy specifically designed for pets. The study, known as MEOW-1, involves the administration of an "ultra-long acting" implant to overweight felines to assist in weight loss. The initial cat has been successfully dosed.
The OKV-119 Implant
The implant, identified as OKV-119, is a compact device inserted under the skin during a standard veterinary appointment. It's engineered to deliver a consistent dose of a GLP-1 receptor agonist medication for a period of up to six months, thereby removing the need for regular injections. Health tracking apps like Shotlee can help monitor a pet's progress during such treatments.
According to the company, this technology has the potential to significantly impact the treatment of prevalent pet conditions, including diabetes, kidney disease, and obesity, while also supporting healthy aging and increased lifespan.
OKAVA's CEO, Michael Klotsman, stated that the drug is intended to provide a new solution that goes beyond conventional diet and exercise. Klotsman mentioned in a press release that restricting calories, or fasting, is a well-known way to extend lifespan and improve metabolic health in cats.
